170 related articles for article (PubMed ID: 29192345)
1. Transporter-Mediated Interaction Between Platinum Drugs and Sorafenib at the Cellular Level.
Schneider V; Chaib S; Spanier C; Knapp M; Moscvin V; Scordovillo L; Ewertz A; Jaehde U; Kalayda GV
AAPS J; 2017 Nov; 20(1):9. PubMed ID: 29192345
[TBL] [Abstract][Full Text] [Related]
2. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Jaehde U
J Inorg Biochem; 2012 Nov; 116():1-10. PubMed ID: 23010323
[TBL] [Abstract][Full Text] [Related]
3. Contribution of intracellular ATP to cisplatin resistance of tumor cells.
Schneider V; Krieger ML; Bendas G; Jaehde U; Kalayda GV
J Biol Inorg Chem; 2013 Feb; 18(2):165-174. PubMed ID: 23183891
[TBL] [Abstract][Full Text] [Related]
4. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.
Blair BG; Larson CA; Safaei R; Howell SB
Clin Cancer Res; 2009 Jul; 15(13):4312-21. PubMed ID: 19509135
[TBL] [Abstract][Full Text] [Related]
5. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.
Helleman J; Burger H; Hamelers IH; Boersma AW; de Kroon AI; Stoter G; Nooter K
Cancer Biol Ther; 2006 Aug; 5(8):943-9. PubMed ID: 16775422
[TBL] [Abstract][Full Text] [Related]
6. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.
Heim M; Scharifi M; Zisowsky J; Jaehde U; Voliotis D; Seeber S; Strumberg D
Anticancer Drugs; 2005 Feb; 16(2):129-36. PubMed ID: 15655409
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.
Webb T; Carter J; Roberts JL; Poklepovic A; McGuire WP; Booth L; Dent P
Cancer Biol Ther; 2015; 16(11):1660-70. PubMed ID: 26417912
[TBL] [Abstract][Full Text] [Related]
8. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.
Howell SB; Safaei R; Larson CA; Sailor MJ
Mol Pharmacol; 2010 Jun; 77(6):887-94. PubMed ID: 20159940
[TBL] [Abstract][Full Text] [Related]
9. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells.
Zisowsky J; Koegel S; Leyers S; Devarakonda K; Kassack MU; Osmak M; Jaehde U
Biochem Pharmacol; 2007 Jan; 73(2):298-307. PubMed ID: 17097621
[TBL] [Abstract][Full Text] [Related]
10. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
Holzer AK; Manorek GH; Howell SB
Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
[TBL] [Abstract][Full Text] [Related]
11. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
[TBL] [Abstract][Full Text] [Related]
12. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
13. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae.
Lin X; Okuda T; Holzer A; Howell SB
Mol Pharmacol; 2002 Nov; 62(5):1154-9. PubMed ID: 12391279
[TBL] [Abstract][Full Text] [Related]
14. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
[TBL] [Abstract][Full Text] [Related]
15. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.
Kim ES; Tang X; Peterson DR; Kilari D; Chow CW; Fujimoto J; Kalhor N; Swisher SG; Stewart DJ; Wistuba II; Siddik ZH
Lung Cancer; 2014 Jul; 85(1):88-93. PubMed ID: 24792335
[TBL] [Abstract][Full Text] [Related]
16. Stimulatory effects of sorafenib on human non‑small cell lung cancer cells in vitro by regulating MAPK/ERK activation.
Zhang YN; Wu XY; Zhong N; Deng J; Zhang L; Chen W; Li X; Zhong CJ
Mol Med Rep; 2014 Jan; 9(1):365-9. PubMed ID: 24213303
[TBL] [Abstract][Full Text] [Related]
17. [Inhibition of ABC-transporter(s)' function in non-small cell lung cancer cells by platinum drugs].
Bogush TA; Konukhova AV; Ravcheeva AB; Zabotina TN; Kadagidze ZG; Bogush EA; Komov DV; Polotskiĭ BE; Laktionov KK; Davydov MI
Antibiot Khimioter; 2003; 48(10):11-5. PubMed ID: 15004974
[TBL] [Abstract][Full Text] [Related]
18. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
[TBL] [Abstract][Full Text] [Related]
19. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells.
Beretta GL; Gatti L; Tinelli S; Corna E; Colangelo D; Zunino F; Perego P
Biochem Pharmacol; 2004 Jul; 68(2):283-91. PubMed ID: 15194000
[TBL] [Abstract][Full Text] [Related]
20. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs.
Larson CA; Blair BG; Safaei R; Howell SB
Mol Pharmacol; 2009 Feb; 75(2):324-30. PubMed ID: 18996970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]